



Overview peer reviewed scientific publications of the Belgian Cancer Registry

2022

- 1) Gorasso V., Silversmit G., Arbyn M., Cornez A., De Pauw R., De Smedt D., Grant I, Wyper G., Brecht Devleesschauwerv B. & Speybroeck N. **The non-fatal burden of cancer in Belgium, 2004–2019: a nationwide registry-based study.** 2022 *BMC Cancer* <https://doi.org/10.1186/s12885-021-09109-4>
- 2) Daneels W., Rosskamp M., Macq G, Saadoon EI, De Geyndt A., Offner F. and Poirel HA. **Real-World Estimation of First- and Second-Line Treatments for Diffuse Large B-Cell Lymphoma Using Health Insurance Data: A Belgian Population-Based Study.** 2022. *Front. Oncol.* 12:824704. <https://doi.org/10.3389/fonc.2022.824704>
- 3) Soetewey A., Legrand C., Denuit M. and Silversmit G. **Semi-markov modeling for cancer insurance** 2022. *European Actuarial Journal* <https://doi.org/10.1007/s13385-022-00308-2>
- 4) Ding L., Poelheken K., Greuter MJW, Truyen I., De Schutter H. et al. **Overdiagnosis of invasive breast cancer in population-based breast cancer screening: A short- and long-term perspective.** 2022 *Eur J Cancer* 173 (1-9) <https://authors.elsevier.com/sd/article/S0959804922003781>
- 5) Ding L., Greuter MJW., Truyen I., Goossens M., De Schutter H. et al. **Irregular screening participation increases advanced stage breast cancer at diagnosis: A population-based study.** 2022. *The Breast* 65:61-66 <https://doi.org/10.1016/j.breast.2022.07.004>
- 6) Hoeck S., Janssens S., Van Hal G., Van Herck K. **Self-Reported and Objective Impact of the COVID-19 Pandemic on Planning, Compliance and Timeliness of a Diagnostic Colonoscopy after a Positive FIT Screening Result in the Flemish Colorectal Cancer Screening Program.** *Gastrointestinal Disorders.* 2022; 4(3):129-140. <https://doi.org/10.3390/gidisord4030013>

2021

- 1) Cardoso R, Guo F, Heisser T, Hackl M, Ihle P, De Schutter H., Van Damme N., et al. **Divergent trends in colorectal cancer incidence, mortality, and stage distribution in European countries in the colorectal cancer screening era: an international population-based study.** 2021 *Lancet Oncol* [https://doi.org/10.1016/S1470-2045\(21\)00199-6](https://doi.org/10.1016/S1470-2045(21)00199-6)
- 2) Peacock HM., Tambuyzer T., Verdoodt F., Calay F., Poirel HA., De Schutter H., Francart J., Van Damme N., Van Eycken L. **Decline and incomplete recovery in cancer diagnoses during the COVID-19 pandemic in Belgium: a year-long, population-level analysis.** 2021 *ESMO Open* 6(4) <https://doi.org/10.1016/j.esmoop.2021.100197>



- 3) Izci H, Tambuyzer T, Vandeven J, Xicluna J, Wildiers H, Punie,K, Willers N, Oldenburger E, Van Nieuwenhuysen E, Berteloot P, Smeets A, Nevelsteen I, Deblander A, De Schutter H, Neven P, Silversmit* G, Freija Verdoodt* (*Equal contributions). **Cause of death discordance between death certificates and medical files.** 2021 *Archives of Public Health*. <https://doi.org/10.1186/s13690-021-00637-w>
- 4) Ribeiro S, De Maeyer F, De Man N, Carton S, Cuyle PJ, Veslype C, Borbath I, Demetter P, Van Damme N, Van Eycken L, Vandamme T, Hoorens A, Geboes K. **Lessons learned about appendiceal neuroendocrine neoplasms form data analysis of the Belgian Cancer Registry 2010-2015.** 2021 *Acta Gastro-Enterologica Belgica*; Vol. 84 <https://doi.org/10.51821/84.3.011>
- 5) Van Hemelrijck WMJ, Rosskamp M, De Schutter H, Verdoodt F, Vanthomme K. **Cancer risk among individuals of migrant origin in Belgium during the 2000s – Evidence of migration as a ‘cancer risk transition’?** *Social Science & Medicine* 2021;269:113591 doi: 10.1016/j.socscimed.2020.113591 <https://doi.org/10.1016/j.socscimed.2020.113591>
- 6) Bahadoer RH, Bastiaannet E., Claassen Y.H.M, van der Mark M., van Eycken E., Verbeeck J., et al. **One year excess mortality and treatment in surgically treated patients with colorectal cancer : A EURECCA european comparison.** 2021 *European Journal of Surgical Oncology* doi: 10.1016/j.ejso.2021.01.011 <https://doi.org/10.1016/j.ejso.2021.01.011>
- 7) Katrien Vanthomme, Michael Rosskamp, Harlinde De Schutter and Hadewijch Vandenheede **Lung cancer incidence differences in migrant men in Belgium, 2004-2013: histology-specific analyses.** *BMC cancer* 2021 doi: 10.1186/s12885-021-08038-6 <https://doi.org/10.1186/s12885-021-08038-6>
- 8) Ding L, Jidkova S., Greuter M.J.W, Van Herck K., Goossens M., De Schutter H., Martens P., Van Hal G., de Bock G.H. **The role of socio-demographic factors in the coverage of breast cancer screening: insights from a quantile regression analysis.** 2021 *Frontiers in Public Health, section Life-Course Epidemiology and Social Inequalities in Health* <https://doi.org/10.3389/fpubh.2021.648278>
- 9) Demoury C., Faes C., De Schutter H., Carbonelle S., Rosskamp M., Francart J., et al. **Childhood leukemia near nuclear sites in Belgium : an ecological study at small geographical level.** 2021 *Cancer epidemiology* 1;146(11):3034-3043. doi: 10.1016/j.canep.2021.101910 <https://doi.org/10.1016/j.canep.2021.101910>
- 10) Rosskamp M, Verbeeck J., Sylvie Gadeyne S., Verdoodt F. and De Schutter H. **Socio-Economic Position, Cancer Incidence and Stage at Diagnosis: A Nationwide Cohort Study in Belgium.** *Cancers* 2021, 13, 933 doi: 10.3390/cancers13050933 <https://doi.org/10.3390/cancers13050933>
- 11) Sacchetto L, Rosso S, Comber H, Bouchardy C, Broganelli P, Galceran J, Hackl M, Katalinic A, Louwman M, Robsahm TE, Tryggvadottir L, Tumino R, Van Eycken E, Walsh PM, Zadnik V, Zanetti R. **Skin melanoma deaths within 1 or 3 years from diagnosis in Europe.** *Int J Cancer*. 2021 Jan 26. doi: 10.1002/ijc.33479 <https://10.1002/ijc.33479>



- 12) Lalova T, Negrouk A., Dollé L, Bekaert S, Debucquoy A, Derèze JJ, Valcke P, Kindt EJ, Huys I **An Overview of Belgian Legislation Applicable to Biobank Research and Its Interplay with Data Protection Rules.** In: *Slokenberga S., Tzortzatou O., Reichel J. (eds) GDPR and Biobanking. Law, Governance and Technology Series*, 2021 vol 43. Springer, Cham. https://doi.org/10.1007/978-3-030-49388-2_10
- 13) Reyn, B., Van Eycken, E., Louwman, M., Henau, K., Schreuder, K., Brochez, L., Garmyn, M. and Kukutsch, N. **Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries.** *J Eur Acad Dermatol Venereol.* 2021 : <https://doi.org/10.1111/jdv.17197>
- 14) George G., Garmo H., Scailteux L-M. , Balusson F., De Coster G., De Schutter H., Kuiper J.G., Oger E., Verbeeck J., Van Hemelrijck M. **Risk of cardiovascular disease following GnRH agonists versus antagonists in prostate cancer: Real-world evidence from five databases.** *Int. J. Cancer* 2020 148(9):2203-2211 doi.org/10.1002/ijc.33397 <https://doi.org/10.1002/ijc.33397>
- 15) Verleye L, De Gendt C, Leroy R, Stordeur S, Schillemans V, Savoye I, Silversmit G, Van Eycken L, Daisne JF, Nuyts S, Vermorken J, Grégoire V. **Patterns and quality of care for head and neck carcinoma in Belgium: a population-based study.** *European Journal of Cancer Care* 2021. <https://doi.org/10.1111/ecc.13454> .
- 16) Huang L , Jansen L., H.A. Verhoeven R., Ruurda J.P, Van Eycken L., De Schutter H., et al... **Largely varying patterns and trends of primary cancer-directed resection for gastric carcinoma with synchronous distant metastasis in Europe and the US: a population-based study calling for further standardization of care.** *Ther Adv Med Oncol* 2021, Vol. 13: 1–14 <https://doi.org/10.1177/17588359211027837>
- 17) Ocak S., Tournoy K.G., Berghmans T., Demedts I., Durieux R., et al... Van Eycken L., ... **Lung cancer in Belgium.** 2021 *Journal of Thoracic Oncology* 16(10): 1610-1621 <https://doi.org/10.1016/j.jtho.2021.07.022>
- 18) Silversmit G., Verdoodt F., Van Damme N., De Schutter H., and Van Eycken L. **Excess Mortality in a Nationwide Cohort of Cancer Patients during the Initial Phase of the COVID-19 Pandemic in Belgium.** 2021 *Cancer Epidemiol Biomarkers Prev* 30, p1615–1619 <https://doi.org/10.1158/1055-9965.EPI-21-0230>
- 19) Reyn B., Van Eyken E., Louwman M., Henau K., Schreuder K., Brochez L., Garmyn M., Kukutsch NA. **Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries.** 2021 *JEADV* 35, 1528–153 <https://doi.org/10.1111/jdv.17197>
- 20) Pironet A., Poirel HA., Tambuyzer T., De Schutter H., van Walle L., Mattheijssens J., Henau K., Van Eycken L., Van Damme N. **Machine Learning-Based Extraction of Breast Cancer Receptor Status From Bilingual Free-Text Pathology Reports** 2021 *Front. Digit. Health* <https://doi.org/10.3389/fdgth.2021.692077>



- 1) Stordeur S, Schillemans V, Savoye I, Vanschoenbeek K, Leroy R, Macq G, Verleye L, De Gendt C, Nuyts S, Vermorken J, Beguin C, Grégoire V, Van Eycken L. **Comorbidity in head and neck cancer: Is it associated with therapeutic delay, post-treatment mortality and survival in a population-based study?** *Oral Oncology* 2020;102: . doi: 10.1016/j.oraloncology.2019.104561 <https://doi.org/10.1016/j.oraloncology.2019.104561> .
- 2) Tosco, L., Devos, G., De Coster, G., Roumeguère, T., Everaerts, W., Quackels, T., Dekuyper, P., Van Cleynenbreugel, B., Van Damme, N., Van Eycken, E., Ameye, F., Joniau, S., **Be-RALP (Belgian Robotic-Assisted Laparoscopic Pros, Development and external validation of a nomogram to predict lymph node invasion after robot assisted radical prostatectomy.** *Urol Oncol* 2020, 38 (2), 37.e11-37.e20. doi: 10.1016/j.urolonc.2019.10.001 <https://doi.org/10.1016/j.urolonc.2019.10.001>
- 3) Nevens D., Kindts I., Defourny N., Boesmans L., Van Damme N., Engels H., Van de Voorde C. and Lievens Y. **The financial impact of SBRT for oligometastatic disease: A population-level analysis in Belgium.** *Radiotherapy and Oncology* 2020, 145 : 215-222. doi: 10.1016/j.radonc.2020.01.024 <https://doi.org/10.1016/j.radonc.2020.01.024>
- 4) Guo F., De Brabander I., Francart J., Candeur M., Polus M., Van Eycken L. and Brenner H. **Benefits of switching from guaiac-based faecal occult blood to faecal immunochemical testing: experience from the Wallonia-Brussels colorectal cancer screening programme.** *Br J Cancer* 2020, 122 : 1109-1117 doi: 10.1038/s41416-020-0754-5 <https://doi.org/10.1038/s41416-020-0754-5>
- 5) Leroy R, Silversmit G, Stordeur S, De Gendt C, Verleye L, Schillemans V, Savoye I, Van Eycken L, Deron P, Hamoir M, Vermorken J, Grégoire V, Nuyts S. **Improved survival in head and neck cancer patients treated in high volume centres: A population-based study in Belgium.** *European Journal of Cancer* 2020; 130:81-91. doi: 10.1016/j.ejca.2020.01.024 <https://doi.org/10.1016/j.ejca.2020.01.024>
- 6) Demoury C., De Schutter H., Faes C., Carbonnelle S., Molenberghs G., Van Damme N., Van Nieuwenhuysse A. and Vleminckx C. **Thyroid cancer incidence near nuclear sites in Belgium: and ecological study at small geographical level.** *International Journal of Cancer* 2019 <https://doi.org/10.1002/ijc.32796>
- 7) Geldof T., Van Damme N., Huys I., Van Dyck W. **Patient-Level Effectiveness Prediction Modeling for Glioblastoma Using Classification Trees.** *Front Pharmacol.* 2020 Jan 31;10:1665. doi: 10.3389/fphar.2019.01665. <https://doi.org/10.3389/fphar.2019.01665> eCollection 2019.
- 8) Geldof T., Popovic D., Van Damme N., Huys I., Van Dyck W. **Nearest Neighbour Propensity Score Matching and Bootstrapping for Estimating Binary Patient Response in Oncology: A Monte Carlo Simulation.** *Sci Rep.* 2020 Jan 22;10(1):964. doi: 10.1038/s41598-020-57799-w. <https://doi.org/10.1038/s41598-020-57799-w>



- 9) Draulans C., Van Damme N., Isebaert S., Everaerts W., Silversmit G., Joniau S., De Meerleer G., Van Eycken E., Haustermans K., on behalf of Be-RALP. **Variation in adjuvant and early salvage radiotherapy after robot-assisted radical prostatectomy for prostate cancer: a population based cohort study.** *Acta Oncologica* 2020 59(8): 904-910 doi: 10.1080/0284186X.2020.1759824 <https://doi.org/10.1080/0284186X.2020.1759824>
- 10) Soetewey A., Legrand, C., Denuit, M. Silversmit G. **Waiting period from diagnosis for mortgage insurance issued to cancer survivors.** *Eur. Actuar. J.* (2020). doi.org/10.1007/s13385-020-00254-x <https://doi.org/10.1007/s13385-020-00254-x>
- 11) Roskamp M., Verbeeck J., Sass V., Gadeyne S., Verdoodt F., De Schutter H. **Social inequalities Social Inequalities in Cancer Survival in Belgium: A Population-Based Cohort Study** *Cancer Epidemiol Biomarkers Prev* 2020 doi: 10.1158/1055-9965.EPI-20-072 <https://10.1158/1055-9965.EPI-20-072>
- 12) Van Hemelrijck W, De Schutter H., de Valk H.A.G., Silversmit G., Roskamp M., Vandenheede H. **Breast cancer by migrant background in Belgium: lower risk, but worse survival in women of non-European origin.** *Int. J. Cancer* 2020 147, 350–360 DOI: 10.1002/ijc.32726 <https://10.1002/ijc.32726>
- 13) Debuquoy A., Linsen L, T'Joel V, Dollé L, Bekaert S. **Editorial: Biobanks as Essential Tools for Translational Research: The Belgian Landscape.** *Front Med.* 2020 Jul 28;7:378. doi: 10.3389/fmed.2020.00378 <https://10.3389/fmed.2020.00378>
- 14) Eklund N, Andrianarisoa NH, van Enkevort E, Anton G, Debuquoy A., et al. **Extending the Minimum Information About Biobank Data Sharing Terminology to Describe Samples, Sample Donors, and Events.** *Biopreserv Biobank.* 2020 18(3):155-164. doi: 10.1089/bio.2019.0129 <https://10.1089/bio.2019.0129>
- 15) Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M., Poirel HA.,, Macq G., et al. **Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).** *Bone Marrow Transplant* 2020 55(4):681-694. doi: 10.1038/s41409-019-0718-7. <https://10.1038/s41409-019-0718-7>
- 16) Snowden JA, Saccardi R, Orchard K, Ljungman P, Duarte RF, Labopin M.... Poirel HA.,, Macq G., et al. **Correction: Benchmarking of survival outcomes following haematopoietic stem cell transplantation: A review of existing processes and the introduction of an international system from the European Society for Blood and Marrow Transplantation (EBMT) and the Joint Accreditation Committee of ISCT and EBMT (JACIE).** *Bone Marrow Transplant.* 2020 55(4):838-839. doi: 10.1038/s41409-019-0740-9. <https://10.1038/s41409-019-0740-9>



- 17) Huang L, Jansen L, Balavarca Y, Verhoeven RHA, Ruurda JP, Van Eycken L, De Schutter H, Johansson J, Lindblad M, Johannesen TB, Zadnik V, Žagar T, Mägi M, Bastiaannet E, Lagarde SM, van de Velde CJH, Schrotz-King P, Brenner H. **Decreasing resection rates for nonmetastatic gastric cancer in Europe and the United States.** *Clin Transl Med.* 2020 Oct;10(6):e203. doi: 10.1002/ctm2.203 <https://10.1002/ctm2.203>

- 18) Gupta S, Aitken J, Bartels U, Bhakta N, ..., Van Eycken L, Vora T, Frazier AL. **Development of paediatric non-stage prognosticator guidelines for population-based cancer registries and updates to the 2014 Toronto Paediatric Cancer Stage Guidelines.** *Lancet Oncol.* 2020 Sep;21(9):e444-e451. doi: 10.1016/S1470-2045(20)30320-X [https://10.1016/S1470-2045\(20\)30320-X](https://10.1016/S1470-2045(20)30320-X)

- 19) Izci H, Tambuyzer T, Tuand K, Depoorter V, Laenen A, Wildiers H, Vergote I, Van Eycken L, De Schutter H, Verdoodt F, Neven P. **A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data.** *J Natl Cancer Inst.* 2020 Oct 1;112(10):979-988. doi: 10.1093/jnci/djaa050 <https://10.1093/jnci/djaa050>

- 20) Minicozzi P, Vicentini M, Innos K, Castro C, Guevara M, Stracci F, Carmona-Garcia M, Rodriguez-Barranco M, Vanschoenbeek K, Rapiti E, Katalinic A, Marcos-Gragera R, Van Eycken L, Sánchez MJ, Bielska-Lasota M, Rossi PG, Sant M; European HR Working Group on colorectal cancer. **Comorbidities, timing of treatments, and chemotherapy use influence outcomes in stage III colon cancer: A population-based European study.** *Eur J Surg Oncol.* 2020 Jun;46(6):1151-1159. doi: 10.1016/j.ejso.2020.02.023 <https://10.1016/j.ejso.2020.02.023>

- 21) Hava I, Tambuyzer T., Tuand K., Depoorter V., Laenen A., Wildiers H., Vergote I., Van Eycken L., De Schutter H., Verdoodt F. and Neven P. **A Systematic Review of Estimating Breast Cancer Recurrence at the Population Level With Administrative Data.** *JNCI* 2020; 112(10):979-988, <https://doi.org/10.1093/jnci/djaa050>

- 22) Groen JV, Douwes TA, van Eycken E, van der Geest LGM, Johannesen TB, Besselink MG, Koerkamp BG, Wilmink JW, Bonsing BA, Portielje JEA, van de Velde CJH, Bastiaannet E, Mieog JSD; Dutch Pancreatic Cancer Group. **Treatment and Survival of Elderly Patients with Stage I-II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium.** *Ann Surg Oncol.* 2020 Dec;27(13):5337-5346. doi: 10.1245/s10434-020-08539-x <https://10.1245/s10434-020-08539-x>

- 23) Soenens C, Dekuyper P, De Coster G, Van Damme N, Van Eycken E, Quackels T, Roumeguère T, Van Cleynebreugel B, Joniau S, Ameye F; Be-RALP registry. **Concordance Between Biopsy and Radical Prostatectomy Gleason Scores: Evaluation of Determinants in a Large-Scale Study of Patients Undergoing RARP in Belgium.** *Pathol Oncol Res.* 2020 Oct;26(4):2605-2612. doi: 10.1007/s12253-020-00860-w <https://10.1007/s12253-020-00860-w>

- 24) Hoeck S, van de Veerdonk W, De Brabander I. **Do socioeconomic factors play a role in nonadherence to follow-up colonoscopy after a positive faecal immunochemical test in the Flemish colorectal cancer**



screening programme? *Eur J Cancer Prev.* 2020 Mar;29(2):119-126. doi: 10.1097/CEJ.0000000000
<https://10.1097/CEJ.0000000000>

- 25) Toes-Zoutendijk E, Portillo I, Hoeck S, de Brabander I, Perrin P, Dubois C, van Leerdam M, Lansdorp-Vogelaar I, Bardou M. **Participation in faecal immunochemical testing-based colorectal cancer screening programmes in the northwest of Europe.** *J Med Screen.* 2020 Jun;27(2):68-76. doi: 10.1177/0969141319879712. <https://10.1177/0969141319879712>
- 26) van Kleef JJ, van den Boorn HG, Verhoeven RHA, Vanschoenbeek K, Abu-Hanna A, Zwinderman AH, Sprangers MAG, van Oijen MGH, De Schutter H, van Laarhoven HWM. **External Validation of the Dutch SOURCE Survival Prediction Model in Belgian Metastatic Oesophageal and Gastric Cancer Patients.** *Cancers* (Basel). 2020 Mar 31;12(4):834. doi: 10.3390/cancers12040834. <https://10.3390/cancers12040834>
- 27) Decallonne B., Van den Bruel A., Macq G., Elaut N., De Schutter H. **The impact of regional variation in clinical practice on thyroid cancer diagnosis: a national population-based study.** *European Thyroid Journal* 2019 Jan;9(1):32-39 <https://doi.org/10.1159/000504046>
- 28) van de Veerdonk W, Hoeck S, Peeters M, Van Hal G, Francart J, De Brabander I. **Occurrence and characteristics of faecal immunochemical screen-detected cancers vs non-screen-detected cancers: Results from a Flemish colorectal cancer screening programme.** *United European Gastroenterol J.* 2020 Mar;8(2):185-194. doi: 10.1177/2050640619882157 <https://10.1177/2050640619882157>
- 29) Bielska-Lasota M, Rossi S, Krzyżak M, Haelens A, Domenic A, De Angelis R, Maciejczyk A, Rodríguez-Barranco M, Zadnik V, Minicozzi P, EURO CARE-5 Working Group. **Reasons for low cervical cancer survival in new accession European Union countries: a EURO CARE-5 study.** *Arch Gynecol Obstet.* 2020 Feb;301(2):591-602. doi: 10.1007/s00404-019-05412-5. <https://10.1007/s00404-019-05412-5>



- 1) Hoeck S., van de Veerdonk W., De Brabander I. and Kellen E. **Does the Flemish colorectal cancer screening programme reach equity in FIT uptake?** *European Journal of Public Health* 2019, vol 0, nr 0 – 1-7. doi: 10.1093/eurpub/ckz043 <https://doi.org/10.1093/eurpub/ckz043>
- 2) Huang L., Balavarca Y., ... Van Eycken E., De Schutter H., et al., **Development and validation of a prognostic model to predict the prognosis of patients who underwent chemotherapy and resection of pancreatic adenocarcinoma: a large international population-based cohort study.** *BMC Med.* 2019, 17:66 doi: 10.1186/s12916-019-1304-y <https://doi.org/10.1186/s12916-019-1304-y>
- 3) Lacroix O., Couttenier A., Vaes E., Cardwell CR., De Schutter H. and Robert A. **Statin use after diagnosis is associated with an increased survival in esophageal cancer patients: a Belgian population-based study.** *Cancer Causes Control* 2019; 30:385-393 doi: 10.1007/s10552-019-01149-3 <https://doi.org/10.1007/s10552-019-01149-3>
- 4) George G., Scailteux L.M., Garmo H., Balusson F., Cardwell C., De Coster G., De Schutter H., Kuiper J.G., McMenamin Ú., Verbeeck J., Van Hemelrijck M. **Real-world insights into risk of developing cardiovascular disease following GnRH agonists versus antagonists for prostate cancer: a methodological protocol to a study using five European databases.** *Fundam Clin Pharmacol.* 2019, 33(4):479-499. doi: 10.1111/fcp.12454. <https://doi.org/10.1111/fcp.12454>
- 5) Schillemans V., Vrijens F., De Gendt C., Robays J., Silversmit G., Verleye L., Camberlin C., Dubois C., Stordeur S., Wauters I., Van Meerbeeck J.P., Van Eycken E., De Leyn P. **Association between surgical volume and post-operative mortality and survival after surgical resection in lung cancer in Belgium: A population-based study.** *Eur J Surg Oncol.* 2019 doi: 10.1016/j.ejso.2019.05.017. <https://doi.org/10.1016/j.ejso.2019.05.017>
- 6) Vande Loock K., Van der Stock E., Debucquoy A., Emmerechts K., Van Damme N. and Marbaix E. on behalf of the steering committee of the Belgian Virtual Tumorbank. **The Belgian Virtual Tumorbank: A Tool for Translational Cancer Research.** *Front. Med.* 2019 <https://doi.org/10.3389/fmed.2019.00120>
- 7) Gatta G., Botta L., Comber H., Dimitrova N., Leinonen M.K., Pritchard-Jones K., Siesling S., Trama A., Van Eycken L., van der Zwan J.M., Visser O., Zagar T., Capocaccia R. **The European study on centralisation of childhood cancer treatment.** *Eur J Cancer.* 2019 115:120-127 doi: 10.1016/j.ejca.2019.04.024 <https://doi.org/10.1016/j.ejca.2019.04.024>
- 8) Claassen Y.H.M., Bastiaannet E., Van Eycken E., Van Damme N., Martling A., Johansson R., Iversen L.H., Ingeholm P., Lemmens V.E.P.P., Liefers G.J., Holman F.A., Dekker J.W.T., Portielje J.E.A., Rutten H.J., van de Velde C.J.H. **Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe.** *Eur J Surg Oncol.* 2019 45(8):1396-1402. doi: 10.1016/j.ejso.2019.03.041 <https://doi.org/10.1016/j.ejso.2019.03.041>



- 9) Poelaert F., Joniau S., Roumeguère T., Ameye F., De Coster G., Dekuyper P., Quackels T., Van Cleynenbreugel B., Van Damme N., Van Eycken E., Mottrie A., Lumen N.; Belgian RALP Consortium **Current Management of pT3b Prostate Cancer After Robot-assisted Laparoscopic Prostatectomy.** *Eur Urol Oncol.* 2019 2(1):110-117. doi: 10.1016/j.euo.2018.05.005 <https://doi.org/10.1016/j.euo.2018.05.005>
- 10) Minicozzi P., Van Eycken L., Molinie F., Innos K., Guevara M., Marcos-Gragera R., Castro C., Rapiti E., Katalinic A., Torrella A., Žagar T., Bielska-Lasota M., Giorgi Rossi P., Larrañaga N., Bastos J., Sánchez M.J., Sant M.; European HR Working Group on breast cancer. **Comorbidities, age and period of diagnosis influence treatment and outcomes in early breast cancer.** *Int J Cancer.* 2019 144(9):2118-2127. doi: 10.1002/ijc.31974 <https://doi.org/10.1002/ijc.31974>
- 11) Couttenier A., Lacroix O., Silversmit G., Vaes E., De Schutter H., Robert A. **Beta-blocker use and mortality following ovarian cancer diagnosis: a population-based study.** *Cancer Epidemiol.* 2019 62:101579. doi: 10.1016/j.canep.2019.101579 <https://doi.org/10.1016/j.canep.2019.101579>
- 12) Poirel H.A., Vanspauwen M., Macq G., De Geyndt A., Maertens J., Willems E., Selleslag D., Poiré X., Theunissen K., Graux C., Kerre T., Zachée P., Meuleman N., De Becker A., Verlinden A., Van Obbergh F., Schuermans C., De Wilde V., Jaspers A., Pranger D., Deeren D., Van Riet I., Vaes E., Beguin Y.; Belgian Transplant Registry and the Belgian Haematological Society's Transplant committee. **Providing both autologous and allogeneic hematopoietic stem cell transplants (HSCT) may have a stronger impact on the outcome of autologous HSCT in adult patients than activity levels or implementation of JACIE at Belgian transplant centres.** *Bone Marrow Transplant.* 2019 54:1434-1442. doi: 10.1038/s41409-019-0458-8 <https://doi.org/10.1038/s41409-019-0458-8>
- 13) Ebo G.D., Blaumeiser B., Kooy F.R., Beckers S., Van Gasse A.L., Saerens M., Sabato V., Poirel HA, **Association of hereditary angioedema type 1 with developmental anomalies due to a large and unusual de novo pericentromeric rearrangement of chromosome 11 spanning the entire C1 inhibitor gene (SERPING1),** *The Journal of Allergy and Clinical Immunology: In Practice* 2019 7(4):1352-1354 <https://doi.org/10.1016/j.jaip.2018.10.005>
- 14) Leroy R, De Gendt C, Stordeur S, Schillemans V, Verleye L, Silversmit G, Van Eycken E, Savoye I, Grégoire V, Nuyts S and Vermorcken J. **Head and Neck Cancer in Belgium: Quality of Diagnostic Management and Variability Across Belgian Hospitals Between 2009 and 2014.** *Frontiers Oncology* 2019;9:1006. <https://doi.org/10.3389/fonc.2019.01006> doi: 10.3389/fonc.2019.01006
- 15) van de Veerdonk W., Hoeck S., Peeters M., Van Hal G., Francart J. and De Brabander I. **Occurrence and characteristics of screen-detected and non-screen-detected cancers after start-up of a regional colorectal cancer screening programme.** *United European Gastroenterology Journal* 2019 1-10 <https://doi.org/10.1177/2050640619882157>



Belgian Cancer Registry

- 16) Goossens M., De Brabander I., De Grève J., Van Ongeval C., Martens P., Van Limbergen E. and Kellen E. **Flemish breast cancer screening programme: 15 years of key performance indicators (2002-2016).** *BMC Cancer* 2019 Oct 28;19(1):1012. doi: 10.1186/s12885-019-6230-z <https://10.1186/s12885-019-6230-z>

- 17) Dheur MS, Poirel HA, Ameye G, Tilman G, Saussoy P, Defour JP, Camboni A, Van Den Neste E, Coulie PG, van Baren N. **Characterization of two new high-grade B-cell lymphoma cell lines with MYC and BCL2 rearrangements that are suitable for in vitro drug sensitivity studies.** *Leuk Lymphoma* 2019 Apr;60(4):1043-1052. doi: 10.1080/10428194.2018.1508663. <https://10.1080/10428194.2018.1508663>

- 18) Macken E., Van Dongen S., De Brabander I., Franque S., Driessen A. and Van Hal G. **Post-colonoscopy colorectal cancer in Belgium: characteristics and influencing factors.** *Endosc Int Open*. 2019 May;7(5):E717-E727. doi: 10.1055/a-0751-2660. <https://doi.org/10.1055/a-0751-2660>



- 1) Hermans B., Vulsteke C., Dekuyper P., Van Baelen A., Huybrechts S., Wulfrank D., Elzo-Kraemer X., Van Eycken E., Ameye F. **Quality of care in oncology: quality indicators in testicular cancer: a hospital-based approach.** *Acta Clinica Belgica*, 2018 73(1):29-33 <https://doi.org/10.1080/17843286.2017.1331814>
- 2) Claassen Y.H.M., Bastiaannet E., Van Eycken E., De Schutter H., et al., **International comparison of treatment strategy and survival in metastatic gastric cancer.** *BJS Open* 2018, 3: 56-61. doi: 10.1002/bjs5.103 <https://doi.org/10.1002/bjs5.103>
- 3) Babaei M., Balavarca Y., Jansen L., Lemmens V., van Erning F.N., Van Eycken L., Vaes E., Sjövall A., Glimelius B., Ulrich C.M., Schrotz-King P. and Brenner H., **Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study.** *Int J Cancer*. 2018 142(7): 1480–1489. <https://doi.org/10.1002/ijc.31168>
- 4) Pusceddu S., Barretta F., Trama A., Botta L., Milione M., Buzzoni R., De Braud F., Mazzaferro V., Pastorino U., Seregni E., Mariani L., Gatta G., Di Bartolomeo M., Femia D., Prinzi N., Coppa J., Panzuto F., Antonuzzo L., Bajetta E., Brizzi M.P., Campana D., Catena L., Comber H., Dwane F., Fazio N., Faggiano A., Giuffrida D., Henau K., Ibrahim T., Marconcini R., Massironi S., Zakelj M.P., Spada F., Tafuto S., Van Eycken E., Van der Zwan J.M., Zagar T., Giacomelli L. and Miceli R. on behalf of NEPscore Working Group, **A classification prognostic score to predict OS in stage IV well differentiated neuroendocrine tumors.** *Endocrine-Related Cancer*, 2018 25(6): 607-618, <https://doi.org/10.1530/ERC-17-0489>
- 5) Derks M.G.M., Bastiaannet E., Kiderlen M., Hilling D.E., Boelens P.G., Walsh P.M., Van Eycken E., Siesling S., Broggio J., Wyld L., Trojanowski M., Kolacinska A., Chalubinska-Fendler J., Gonçalves A.F., Nowikiewicz T., Zegarski W., Audisio R.A., Liefers G.-J., Portielje J.E.A. and van de Velde C.J.H. on behalf of the EURECCA Breast Cancer Group, **Variation in treatment survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group,** *British J of Cancer*, 2018 119: 121-129 doi: 10.1038/s41416-018-0090-1 <https://doi.org/10.1038/s41416-018-0090-1>
- 6) Vrijens F., De Gendt C., Verleye L., Robays J., Schillemans V., Camberlin C., Stordeur S., Dubois C., Van Eycken E., Wauters I. and Van Meerbeeck J.P., **Quality of care and variability in lung cancer management across Belgian hospitals: a population-based study using routinely available data,** *International Journal for Quality in Health Care*, 2018, 30(4):306-312. <https://doi.org/10.1093/intqhc/mzy027>
- 7) Roskamp M., De Schutter H., Henau K., Nackaerts K., Van Meerbeeck J.P., Praet M. and Van Eycken L., **Assessing the completeness and correctness of the registration of malignant mesothelioma in Belgium,** *Lung Cancer* 2018 122: 38-43. <https://doi.org/10.1016/j.lungcan.2018.05.018>



- 8) Roskamp M., Macq G., Nackaerts K., Praet M., Van Eycken L., Van Meerbeeck J.P., De Schutter H., **Real-life treatment practice for malignant pleural mesothelioma in Belgium**, *Lung Cancer* 2018 125: 258-264. <https://doi.org/10.1016/j.lungcan.2018.10.009>

- 9) Tosco L., De Coster G., Roumeguère T., Everaerts W., Quackels T., Dekuyper P., Van Cleynenbreugel B., Van Damme N., Van Eycken E., Ameye F., Joniau S. for the Be-RALP: The Belgian RALP consortium, **Development and external validations of nomograms to predict adverse pathological characteristics after robotic prostatectomy: results of a prospective, multi-institutional, nationwide series**, *Eur Urol Oncol.* 2018 1(4):338-345 <https://doi.org/10.1016/j.euo.2018.04.008>

- 10) Dubois C., De Schutter H., Leroy R., Stordeur S., De Gendt C., Schillemans V., Kohn L., Van Eycken L., Vrijens F., **Multidisciplinary work in oncology: Population-based analysis for seven invasive tumours**, *European Journal of cancer care* 2018 27(2): e12822. <https://doi.org/10.1111/ecc.12822>

- 11) Huang L., Jansen L., Balavarca Y., van der Geest L., Lemmens V., Van Eycken L., De Schutter H., Primic-Zakelj M., Zadnik V, Mägi M., Putte D., Schrotz-King P., Brenner H., **Non-surgical therapies for resected and unresected pancreatic cancer in Europe and USA in 2003-2014: A large international population-based study**, *Int J Cancer*, 2018, 143(12):3227-3239 <https://doi.org/10.1002/ijc.31628>

- 12) Kellen E., Benoy I., Vanden Broeck D., Martens P., Bogers J.P., Haelens A., Van Limbergen E. **A randomized, controlled trial of two strategies of offering the home-based HPV self-sampling test to non-participants in the Flemish cervical cancer screening program.** *Int J cancer* 2018 143(4): 861-868 <https://doi.org/10.1002/ijc.31391>

- 13) Boniol M., Franchi M., Bota M., Leclercq A., Guillaume J., Van Damme N., Corrao G., Autier P., Boyle P. **Incretin-based therapies and the short-term risk of pancreatic cancer: results from two retrospective cohort studies.** *Diabetes Care* 2018 41(2): 286-292. <https://doi.org/10.2337/dc17-0280>

- 14) Heimann P., Poirel H.A., **Cytogenetic and molecular testing in lymphoma patients part1: (cyto)genetic methods, B and T cell clonalities and aberrations in mature B-cell lymphoma's**, *Belg J Hematol.* 2018 9(6):225-236 https://www.aries.nl/wp-content/uploads/2018/11/BJH6_2018_Art_Heimann.pdf

- 15) Poirel H.A., Heimann P., **Cytogenetic and molecular testing in lymphoma patients part2: Aberrations in aggressive B-cell lymphomas, Hodgkin lymphoma and T and NK lymphomas.** *Belg J Hematol.* 2018 9(7): 266-278 https://www.aries.nl/wp-content/uploads/2019/01/BJH7_2018_Art_Heimann.pdf

- 16) Poirel H.A., Ambrosio M.R., Piccaluga P.P., **Pathology and molecular pathogenesis of Burkitt lymphoma and lymphoblastic lymphoma.** *Aggressive lymphomas, Hematologic Malignancies.* 2018 75-94 http://dx.doi.org/10.1007/978-3-030-00362-3_3



- 17) Claassen Y.H.M., Dikken J.L., Hartgrink H.H., de Steur W.O., Slingerland M., Verhoeven R.H.A, Van Eycken E., De Schutter H., Johansson J., Rouvelas I., Johnson E., Hjortland G.O., Jensen L.S., Larsson H.J., Allum W.H., Portiejle J.E.A., Bastiaannet E., van de Velde C.J.H **North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis.** *Eur J Surg Oncol* 2018 44(12): 1982-1989 <https://doi.org/10.1016/j.ejso.2018.09.014>

- 18) Huang L., Jansen L., Balavarca Y., Babaei M., van der Geest L., Lemmens V., Van Eycken L., De Schutter H., Johannesen T.B., Primic-Zakelj M., Zadnik V., Besselink M.G., Schrotz-King P. and Brenner H. **Stratified survival of resected and overall pancreatic cancer patients in Europe and the USA in the early twenty-first century: a large, international population-based study.** 2018. *BMC Med* 16(1): 38-43. <https://doi.org/10.1186/s12916-018-1120-9>

- 19) Lacroix O., Couttenier A., Vaes E., Cardwell CR., De Schutter H. and Robert A. **Impact of metformin on gastric adenocarcinoma survival: a Belgian population-based study.** *Cancer Epidemiol* 2018; 53:149-155 <https://doi.org/10.1016/j.canep.2018.02.001>

- 20) Jegou D., Dubois C., Schillemans V., Stordeur S., De Gendt C., Camberlin C., Verleye L., Vrijens F. **Use of health insurance data to identify and quantify the prevalence of main comorbidities in lung cancer patients.** *Lung Cancer.* 2018 125: 238-244 doi: 10.1016/j.lungcan.2018.10.002 <https://doi.org/10.1016/j.lungcan.2018.10.002>

- 21) van de Veerdonk W., Van Hal G., Peeters M., De Brabander I., Silversmit G., Hoeck S.. **Risk stratification for colorectal neoplasia detection in the Flemish colorectal cancer screening programme.** *Cancer Epidemiol.* 2018 56:90-96. doi: 10.1016/j.canep.2018.07.015. <https://doi.org/10.1016/j.canep.2018.07.015>

- 22) Weberpals J., Jansen L., Silversmit G., Verbeeck J., van der Geest L., Vissers P.A., Zadnik V., Brenner H. **Comparative performance of a modified landmark approach when no time of treatment data are available within oncological databases: exemplary cohort study among resected pancreatic cancer patients.** *Clin Epidemiol.* 2018 10: 1109-1125. doi: 10.2147/CLEP.S160973. <https://doi.org/10.2147/CLEP.S160973>

- 23) Groen J.V., Sibinga Mulder B.G., Van Eycken E., Valerianova Z., Borrás J.M., van der Geest L.G.M., Capretti G., Schlesinger-Raab A., Primic-Zakelj M., Ryzhov A., van de Velde C.J.H., Bonsing B.A., Bastiaannet E., Mieog J.S.D. **Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium.** *Ann Surg Oncol.* 2018 25(12): 3492-3501. doi: 10.1245/s10434-018-6705-1. <https://doi.org/10.1245/s10434-018-6705-1>

- 24) Claassen Y.H.M., Vermeer N.C.A., Iversen L.H., Van Eycken E., Guren M.G., Mroczkowski P., Martling A., Codina Cazador A., Johansson R., Vandendael T., Wibe A., Moller B., Lippert H., Rutten H.J.T., Portielje J.E.A., Liefers G.J., Holman F.A., van de Velde C.J.H., Bastiaannet E. **Treatment and survival of rectal cancer patients over the age of 80 years: a EURECCA international comparison.** *Br J Cancer* 2018 119(4):517-522. doi: 10.1038/s41416-018-0215-6 <https://doi.org/10.1038/s41416-018-0215-6>



- 25) Breugom A.J., Bastiaannet E., Boelens P.G., Van Eycken E., Iversen L.H., Martling A., Johansson R., Evans T., Lawton S., O'Brien K.M., Ortiz H., Janciauskiene R., Dekkers O.M., Rutten H.J.T., Liefers G.J., Lemmens V.E.P.P., van de Velde C.J.H. **Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania.** *Eur J Surg Oncol.* 2018 44(9):1338-1343. doi: 10.1016/j.ejso.2018.05.025. <https://doi.org/10.1016/j.ejso.2018.05.025>
- 26) Derks M.G.M., Bastiaannet E., Kiderlen M., Hilling D.E., Boelens P.G., Walsh P.M., Van Eycken E., Siesling S., Broggio J., Wyld L., Trojanowski M., Kolacinska A., Chalubinska-Fendler J., Gonçalves A.F., Nowikiewicz T., Zegarski W., Audisio R.A., Liefers G.J., Portielje J.E.A., van de Velde C.J.H.; EURECCA Breast Cancer Group. **Variation in treatment and survival of older patients with non-metastatic breast cancer in five European countries: a population-based cohort study from the EURECCA Breast Cancer Group.** *Br J Cancer.* 2018 119(1):121-129. doi: 10.1038/s41416-018-0090-1 <https://doi.org/10.1038/s41416-018-0090-1>
- 27) Vermeer N.C.A., Claassen Y.H.M., Derks M.G.M., Iversen L.H., Van Eycken E., Guren M.G., Mroczkowski P., Martling A., Johansson R., Vandendael T., Wibe A., Moller B., Lippert H., Portielje J.E.A., Liefers G.J., Peeters K.C.M.J., van de Velde C.J.H., Bastiaannet E. **Treatment and Survival of Patients with Colon Cancer Aged 80 Years and Older: A EURECCA International Comparison.** *Oncologist.* 2018 23(8):982-990. doi: 10.1634/theoncologist.2017-0551 <https://doi.org/10.1634/theoncologist.2017-0551>
- 28) Sacchetto L., Zanetti R., Comber H., Bouchardy C., Brewster D.H., Broganelli P., Chirlaque M.D., Coza D., Galceran J., Gavin A., Hackl M., Katalinic A., Larønningen S., Louwman M.W.J., Morgan E., Robsahm T.E., Sanchez M.J., Tryggvadóttir L., Tumino R., Van Eycken E., Vernon S., Zadnik V., Rosso S. **Trends in incidence of thick, thin and in situ melanoma in Europe.** *Eur J Cancer.* 2018 92:108-118. doi: 10.1016/j.ejca.2017.12.024. <https://doi.org/10.1016/j.ejca.2017.12.024>
- 29) Bastiaannet E., Charman J., Johannesen T.B., Schrodi S., Siesling S., Van Eycken L., Walsh P.M., Audisio R.A., Boelens P.G., Rubio I.T., Jones N., Lewis J., van de Velde C.J.H. **A European, Observational Study of Endocrine Therapy Administration in Patients With an Initial Diagnosis of Hormone Receptor-Positive Advanced Breast Cancer.** *Clin Breast Cancer.* 2018 18(4):e613-e619. doi: 10.1016/j.clbc.2017.11.019 <https://doi.org/10.1016/j.clbc.2017.11.019>
- 30) Bollaerts K., Simons K., Van Bladel L., De Smedt T., Sonck M., Fierens S., Poffijn A., Geraets D., Gosselin P., Van Oyen H, Francart J. Van Nieuwenhuyse A. **Childhood Leukaemia near Nuclear Sites in Belgium, 2002-2008.** *Eur J Canc Prev,* 2018 27(2): 184-191 doi: 10.1097/CEJ.0000000000000272 <https://doi.org/10.1097/CEJ.0000000000000272>



- 1) Huang L., Jansen L., Balavarca Y., Molina-Montes E., Babaei M., van der Geest L., Lemmens V., Van Eycken E., De Schutter H., Johannesen T.B., Frstrup C.W., Mortensen M.B., Primic-Žakelj M., Zadnik V., Becker N., Hackert T., Mägi M., Cassetti T., Sassatelli R., Grützmänn R., Merkel S., Gonçalves A.F., Bento M.J., Hegyi P., Lakatos G., Szentesi A., Moreau M., van de Velde T., Broeks A., Sant M., Minicozzi P., Mazzaferro V., Real F.X., Carrato A., Molero X., Besselink M.G., Malats N., Büchler M.W., Schrotz-King P., Brenner H. **Resection of pancreatic cancer in Europe and USA: an international large-scale study highlighting large variations.** *Gut.* 2017 68:130-139 <http://dx.doi.org/10.1136/gutjnl-2017-314828>
- 2) Demoury C., De Smedt T., De Schutter H., Sonck M., Van Damme N., Bollaerts K., Molenberghs G., Van Bladel L., Van Nieuwenhuysse A. **Thyroid Cancer Incidence around the Belgian Nuclear Sites, 2000-2014.** *Int J Environ Res Public Health.* 2017 14(9): 988-1000. <https://doi.org/10.3390/ijerph14090988>
- 3) Couttenier A., Lacroix O., Vaes E., Cardwell C.R., De Schutter H., Robert A.. **Statin use is associated with improved survival in ovarian cancer: a retrospective population based study.** *PLOS ONE* 2017 12(12):e0189233. <https://doi.org/10.1371/journal.pone.0189233>
- 4) Lievens Y., De Schutter H., Stellamans K., Roskamp M., Van Eycken L.; Belgian College for Physicians in Radiation Oncology. **Radiotherapy access in Belgium: How far are we from evidence-based utilisation?** *Eur J Cancer.* 2017 84:102-113. <https://doi.org/10.1016/j.ejca.2017.07.011>
- 5) Verleye L., De Gendt C., Vrijens F., Schillemans V., Camberlin C., Silversmit G., Stordeur S., Van Eycken E., Dubois C., Robays J., Wauters I., Van Meerbeeck J.P. **Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study.** *Eur J Cancer Care* 2017 18: 1-8. <https://doi.org/10.1111/ecc.12747>
- 6) Silversmit G., Jegou D., Vaes E., Van Hoof E., Goetghebeur E., Van Eycken L.: **Cure of cancer for seven cancer sites in the Flemish Region.** *Int J Cancer.* 2017 140(5):1102-1110. <https://doi.org/10.1002/ijc.30532>
- 7) Goossens M.C., De Brabander I., De Greve J., Vaes E., Van Ongeval C., Van Herck K., Kellen E.. **Breast cancer risk is increased in the years following false-positive breast cancer screening.** *Eur J Cancer Prev.* 2017 26(5):396-403. <http://dx.doi.org/10.1097/CEJ.0000000000000313>.
- 8) Silversmit G., Vaes E., Van Eycken L. **Estimation of population-based cancer-specific potential years of life lost in Belgium** *Eur J Cancer Prev.* 2017 26:S157-S163. <http://dx.doi.org/10.1097/CEJ.0000000000000385>
- 9) Wauters L.; Billiet T.; Papamichael K. Ballet V. Joniau, S. Verschueren P.; Silversmit G.; Van Assche G. Vermeire S.; Ferrante M., **Incidence of renal cell carcinoma in inflammatory bowel disease patients with and without anti-TNF treatment** *European Journal of Gastroenterology and Hepatology* 2017 29: 84-90, <http://dx.doi.org/10.1097/MEG.0000000000000735>



- 10) Swerdlow A. J., Cooke R., Beckers D., Borgstrom B., Butler G., Carel J.-C., Cianfarani S., Clayton P., Coste J., Deodati A., Ecosse E., Gausche R., Giacomozzi C., Hokken-Koelega A.C.S., Khan A.J., Kiess W., Kuehni C. E., Mullis P.-E., Pfaffle R., Savendahl L., Sommer G., Thomas M., Tidblad A., Tollerfield S., Van Eycken L., Zandwijken G.R.J., **Cancer Risk in Patients Treated With Growth Hormone in Childhood: The SAGhE European Cohort Study.** *J Clin Endocrinol Metab*, 2017, 102(5): 1661-1672, <http://dx.doi.org/10.1210/jc.2016-2046>
- 11) Gatta G., Capocaccia R., Botta L., Mallone S., De Angelis R., Ardanaz E., Comber H., Dimitrova N., Leinonen M.K., Siesling S., van der Zwan J.M., Van Eycken L., Visser O., Žakelj M.P., Anderson L.A., Bella F., Kaire I., Otter R., Stiller C.A., Trama A., for the RARECAREnet working group, **Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet—a population-based study**, *The Lancet Oncology*, 2017. [http://dx.doi.org/10.1016/S1470-2045\(17\)30445-X](http://dx.doi.org/10.1016/S1470-2045(17)30445-X)
- 12) Albisinni S.; Joniau S.; Quackels T.; De Coster G.; Dekuyper P.; Van Cleynenbreugel B.; Van Damme N.; Van Eycken E.; Ameye F.; and Roumeguère T.; Be-RALP Registry (Belgian Robotic-Assisted Laparoscopic Prostatectomy Registry) **Current Trends in Patient Enrollment for Robotic-Assisted Laparoscopic Prostatectomy in Belgium**, *Cancer* 2017 123 (21): 4139-4146. <http://dx.doi.org/10.1002/cncr.30874>
- 13) Timmermans L., Bleyen L., Bacher K., Van Herck K., Lemmens K., Van Ongeval C., Van Steen A., Martens P., De Brabander I., Goossens M., Thierens H. **Screen-detected versus interval cancers: Effect of imaging modality and breast density in the Flemish Breast Cancer Screening Programme.** *Eur Radiol.* 2017 27(9):3810-3819. <http://dx.doi.org/10.1007/s00330-017-4757-4>
- 14) Haelens A., Roche L., Bastos J., Woronoff A.S., Zorzi M., Francart J.; GRELL EUROCARE-5 Working Group. **Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study.** *Eur J Cancer Prev.* 2017 26: S92-S99. <http://dx.doi.org/10.1097/CEJ.0000000000000292>
- 15) O'Sullivan B., Brierley J., Byrd D., Bosman F., Kehoe S., Kossary C., Piñeros M., Van Eycken E., Weir H.K., Gospodarowicz M. **The TNM classification of malignant tumours-towards common understanding and reasonable expectations.** *Lancet Oncol.* 2017 18(7):849-851. doi: 10.1016/S1470-2045(17)30438-2 [https://doi.org/10.1016/S1470-2045\(17\)30438-2](https://doi.org/10.1016/S1470-2045(17)30438-2)
- 16) Walraven I., Damhuis R.A., Ten Berge M.G., Roskamp M., Van Eycken L., de Ruyscher D., Belderbos J.S.A. **Treatment Variation of Sequential versus Concurrent Chemoradiotherapy in Stage III Non-Small Cell Lung Cancer Patients in the Netherlands and Belgium.** *Clin Oncol (R Coll Radiol).* 2017 29(11):e177-e185. doi: 10.1016/j.clon.2017.07.012. <http://dx.doi.org/10.1016/j.clon.2017.07.012>



- 1) Cardwell C.R., Pottegård A., Vaes E., Garmo H., Murray L.J., Brown C., Vissers P.A.J., O'Rorke M., Visvanathan K., Cronin-Fenton D., De Schutter H., Lambe M., Powe D.G., van Herk-Sukel M.P.P., Gavin A., Friis S., Sharp L. and Bennett K.: **Propranolol and survival from breast cancer: a pooled analysis of European breast cancer cohorts.** *Breast Cancer Research* 2016 18:119 <http://dx.doi.org/10.1186/s13058-016-0782-5>
- 2) Op de Beeck B., Smeets P., Penninckx F., Pattyn P., Silversmit G., Van Eycken E.; PROCARE. **Accuracy of pre-treatment locoregional rectal cancer staging in a national improvement project.** *Acta Chir Belg.* 2016 24:104-116 <http://dx.doi.org/10.1080/00015458.2016.1259883>
- 3) Schöffski P., Wozniak A., Schöffski O., Van Eycken L., Debiec-Rychter M. **Overcoming Cost Implications of Mutational Analysis in Patients with Gastrointestinal Stromal Tumors: A Pragmatic Approach.** *Oncol Res Treat.* 2016 39(12):811-816. <http://dx.doi.org/10.1159/000453057>
- 4) Rommens K., Jegou D., De Backer H., Weyler J. **Seasonal variation in cutaneous melanoma incidence, link with recent UV levels: a population-based study in Belgium (2006-2011).** *Melanoma Res* 2016, 26: 195-201. <http://dx.doi.org/10.1097/CMR.0000000000000238>
- 5) Baert T., Storme N., Van Nieuwenhuysen E., Uyttebroeck A., Van Damme N., Vergote I., Coosemans A. **Ovarian cancer in children and adolescents: A rare disease that needs more attention.** *Maturitas.* 2016, 88: 3-8. <http://dx.doi.org/10.1016/j.maturitas.2016.03.003>
- 6) Leroy R., Benahmed N., Hulstaert F., Van Damme N., De Ruyscher D. **Proton Therapy in Children: A Systematic Review of Clinical Effectiveness in 15 Pediatric Cancers.** *Int J Radiat Oncol Biol Phys.* 2016 95(1): 267-78 <http://dx.doi.org/10.1016/j.ijrobp.2015.10.025>
- 7) Callens J., Van Eycken L., Henau K., Garmyn M. **Epidemiology of basal and squamous cell carcinoma in Belgium: the need for a uniform and compulsory registration.** *J. Eur Acad Dermatol Venereol.* 2016 30(11):1912-1918 <http://dx.doi.org/10.1111/jdv.13703>
- 8) Joye I., Silversmit G., Van Eycken E., Debuquoy A., Vandendael T., Penninckx F., Haustermans K. **Survival among clinical stage I-III rectal cancer patients treated with different preoperative treatments: A population-based comparison.** *Cancer Epidemiol.* 2016 43: 35-41. <http://dx.doi.org/10.1016/j.canep.2016.06.007>
- 9) Joye I., Macq G., Vaes E., Roels S., Lambrecht M., Pelgrims A., Bussels B., Vancleef A., Stellamans K., Scalliet P., Weytjens R., Christian N., Boulanger A.S, Donnay L., Van Brussel S., Moretti L., Van den Bergh L., Van Eycken E., Debuquoy A., Haustermans K. **Do refined consensus guidelines improve the uniformity of clinical target volume delineation for rectal cancer? Results of a national review project.** *Radiother Oncol.* 2016, 120(2):202-206 doi: 10.1016/j.radonc.2016.06.005. <https://doi.org/10.1016/j.radonc.2016.06.005>



- 10) Breugom A.J, Bastiaannet E., Boelens P.G, Iversen L.H, Martling A., Johansson R., Evans T., Lawton S., O'Brien K.M, Van Eycken E., Janciauskiene R., Liefers G.J, Cervantes A., Lemmens V.E, van de Velde C.J. **Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania.** *Eur J Cancer*, 63 : 110-117. doi: 10.1016/j.ejca.2016.04.017 <https://doi.org/10.1016/j.ejca.2016.04.017>
- 11) De Leede E.M, Sibinga Mulder B.G, Bastiaannet E., Poston G.J, Sahora K., Van Eycken E., Valerianova Z., Mortensen M.B, Dralle H., Primic- Zakelj M., Borràs J.M, Gasslander T., Ryzhov A., Lemmens V.E., Mieog J.S, Boelens P.G., van de Velde C.J., Bonsing B.A. **Common variables in European pancreatic cancer registries: The introduction of the EURECCA pancreatic cancer project.** *Eur J Surg Oncol*, 2016, 42(9):1414-1419 doi: 10.1016/j.ejso.2016.03.011 <https://doi.org/10.1016/j.ejso.2016.03.011>
- 12) Maetens A., De Schreye R., Faes K., Houttekier D., Deliëns L., Gielen B., De Gendt C., Lusyns P., Annemans L., Cohen J. **Using linked administrative and disease-specific databases to study end-of-life care on a population level**, *BMC Palliat Care*. 2016 15(1):86-96. <https://doi.org/10.1186/s12904-016-0159-7>
- 13) Hoeck S., Pringels S., Kellen E., Van Herck K., Martens P., Van Limbergen E., Francart J., Van Hal G. **First results of the Flemish colorectal cancer screening program: start-up- period late 2013.** *Acta Gastroenterol Belg*. 2016 79(3):421-428.
- 14) Demetter P., Jouret-Mourin A., Silversmit G., Vandendael T., Sempoux C., Hoorens A., Nagy N., Cuvelier C., Van Damme N., Penninckx F and on behalf of PROCARE, **Review of the quality of total mesorectal excision does not improve the prediction of outcome.** *Colorectal Disease* 2016 18: 883-888 <https://doi.org/10.1111/codi.13254>
- 15) I. Tromme, C. Legrand , B. Devleeschauwer , U. Leiter, S. Suciù, A. Eggermont, J. Francart, F. Calay, J. A. Haagsmaï, J.-F. Baurain, L. Thomas k, P. Beutels, N. Speybroeck **Melanoma burden by melanoma stage: Assessment through a disease transition model.** *European Journal of Cancer* 53 (2016) 33-41 <https://doi.org/10.1016/j.ejca.2015.09.016>



- 1) Bollaerts K., Sonck M., Simons K., Fierens S., Poffijn A., Van Bladel L., Geraets D., Gosselin P., Van Oyen H., Francart J., Van Nieuwenhuysse A.: **Thyroid cancer incidence around the Belgian nuclear sites: Surrogate exposure modelling.** *Cancer Epidemiol* 2015, 39(1): 48-54 doi: 10.1016/j.canep.2014.10.011 <https://doi.org/10.1016/j.canep.2014.10.011>
- 2) Borrás J.M., Barton M., Grau C., Corral J., Verhoeven R., Lemmens V., Van Eycken L., Henau K., Primic-Zakelj M., Strojanić P., Trojanowski M., Dyzmann-Sroka A., Kubiak A., Gasparotto C., Defourny N., Malicki J., Dunscombe P., Coffey M., Lievens Y.: **The impact of cancer incidence and stage on optimal utilization of radiotherapy: Methodology of a population based analysis by the ESTRO-HERO project.** *Radiotherapy and Oncology* 2015, 116:45-50. <https://doi.org/10.1016/j.radonc.2015.04.021>
- 3) Borrás J.M., Lievens Y., Dunscombe P., Coffey M., Malicki J., Corral J., Gasparotto C., Defourny N., Barton M., Verhoeven R., Van Eycken L., Primic-Zakelj M., Trojanowski M., Strojanić P., Grau C.: **The optimal utilization proportion of external beam radiotherapy in European countries: An ESTRO-HERO analysis.** *Radiotherapy and Oncology* 2015, 116:38-44. <https://doi.org/10.1016/j.radonc.2015.04.018>
- 4) Damhuis R.A., Khakwani A., De Schutter H., Rich A.L., Burgers J.A., van Meerbeeck J.P.: **Treatment patterns and survival analysis in 9014 patients with malignant pleural mesothelioma from Belgium, the Netherlands and England.** *Lung Cancer* 2015, 89:212-217. <https://doi.org/10.1016/j.lungcan.2015.05.014>
- 5) De Schutter H., Van Damme N., Colpaert C., Galant C., Lambein K., Cornelis A., Neven P., Van Eycken E.: **Quality of pathology reporting is crucial for cancer care and registration: A baseline assessment for breast cancers diagnosed in Belgium in 2008.** *Breast* 2015, 24(2): 143-152. doi:10.1016/j.breast.2014.12.004 <https://doi.org/10.1016/j.breast.2014.12.004>
- 6) Henau K., Van Eycken E., Silversmit G., Pukkala E.: **Regional variation in incidence for smoking and alcohol related cancers in Belgium.** *Cancer Epidemiol* 2015, 39(1): 55 – 65. <https://doi.org/10.1016/j.canep.2014.10.009>
- 7) Jegou D., Penninckx F., Vandendael T., Bertrand C., Van Eycken E., on behalf of PROCARE: **Completeness and registration bias in PROCARE, a Belgian multidisciplinary project on cancer of the rectum with participation on a voluntary basis.** *Eur J Cancer* 2015, 51(9):1099-108 doi: 10.1016/j.ejca.2014.02.025 <https://doi.org/10.1016/j.ejca.2014.02.025>
- 8) Savoye I., Jegou D., Kvaskoff M., Rommens K., Boutron-Ruault M.-C., Coppieters Y., Francart J.: **Is melanoma survival influenced by month of diagnosis?** *Cancer Epidemiology* 2015, 39:727-733 <https://doi.org/10.1016/j.canep.2015.07.003>



- 9) Stordeur S., Vlayen J., Vrijens F., Camberlin C., De Gendt C., Van Eycken E., Lerut T.: **Quality indicators for oesophageal and gastric cancer: a population-based study in Belgium, 2004-2008.** *Eur J Cancer Care* 2015, 24(3):376-86. doi: 10.1111/ecc.12279 <https://doi.org/10.1111/ecc.12279>
- 10) Trama A., Foschi R., Larrañaga N., Sant M., Fuentes-Raspall R., Serraino D., Tavilla A., Van Eycken L., Nicolai N., and the EURO CARE- 5 Working Group: **Survival of male genital cancers (prostate, testis and penis) in Europe 1999–2007: Results from the EURO CARE-5 study.** *European Journal of Cancer* 2015, 51: 2206-2216 <https://doi.org/10.1016/j.ejca.2015.07.027>
- 11) Zanetti R., Schmidtmann I., Sacchetto L., Binder-Foucard F., Bordoni A., Coza D., Ferretti S., Galceran J., Gavin A., Larranaga N., Robinson D., Tryggvadottir L., Van Eycken E., Zadnik V., Coebergh J.W., Rosso S.: **Completeness and timeliness: Cancer registries could/should improve their performance.** *Eur J Cancer* 2015, 51(9):1091-8 doi: 10.1016/j.ejca.2013.11.040 <https://doi.org/10.1016/j.ejca.2013.11.040>

2014

- 1) Bollaerts K., Fierens S., Van Bladel L., Simons K., Sonck M., Poffijn A., Geraets D., Gosselin P., Van Oyen H., Francart J., Van Nieuwenhuysse A.: **Thyroid cancer incidence in the vicinity of nuclear sites in Belgium, 2000-2008.** *Thyroid* 2014, 24(5):906-17. <https://doi.org/10.1089/thy.2013.0227>
- 2) Joye I., Lambrecht M., Jegou D., Hortobágyi E., Scalliet P., Haustermans K.: **Does a central review platform improve the quality of radiotherapy for rectal cancer? Results of a national quality assurance project.** *Radiother Oncol* 2014, 111(3):400-405. <https://doi.org/10.1016/j.radonc.2014.03.003>
- 3) Leonard D., Penninckx F., Kartheuser A., Laenen A., Van Eycken E., on behalf of PROCARE: **Effect of hospital volume on quality of care and outcome after rectal cancer surgery.** *Br J Surg.* 2014, 101(11):1475-82. <https://doi.org/10.1002/bjs.9624>



- 1) Crocetti E., Caldarella A., Ferretti S., Ardanaz E., Arveux P., Bara S., Barrios E., Bento M.J., Bordoni A., Buzzoni C., Candela G., Colombani F., Delafosse P., Federico M., Francart J., Giacomini A., Grosclaude P., Guizard A.V., Izarzugaza I., Konzelmann I., La Rosa F., Lapotre B., Leone N., Ligier K., Mangone L., Marcos-Gragera R., Martinez R., Michelena M.J., Michiara M., Miranda A., Molinié F., Mugarza-Gomez C., Paci E., Piffer S., Puig-Vives M., Sacchetti C., Sánchez M.J., Traina A., Tretarre B., Tumino R., Van Vaerenbergh E., Velten M., Woronoff A.S. **Consistency and inconsistency in testing biomarkers in breast cancer. A GRELL study in cut-off variability in the Romance language countries.** *Breast* 2013, 22(4):476-81. <https://doi.org/10.1016/j.breast.2013.04.012>
- 2) Demetter P., Vandendael T., Sempoux C., Ectors N., Cuvelier C.A., Nagy N., Hoorens A., Jouret-Mourin A. **Need for objective and reproducible criteria in histopathological assessment of total mesorectal excision specimens: lessons from a national improvement project.** *Colorectal Dis* 2013, 15(11):1351-8. <https://doi.org/10.1111/codi.12362>
- 3) Penninckx F., Fieuws S., Beirens K., Demetter P., Ceelen W., Kartheuser A., Molle G., Van de Stadt J., Vindevoghel K., Van Eycken E., on behalf of PROCARE: **Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project.** *Gut* 2013, 62(7):1005-11. <http://dx.doi.org/10.1136/gutjnl-2011-301941>
- 4) Penninckx F., Kartheuser A., Van de Stadt J., Pattyn P., Mansvelt B., Bertrand C., Van Eycken E., Jegou D., Fieuws S., on behalf of PROCARE: **Outcome following laparoscopic and open total mesorectal excision for rectal cancer.** *Br J Surg* 2013, 100(10):1368-75. <https://doi.org/10.1002/bjs.9211>
- 5) Van den Bruel A., Francart J., Dubois C., Adam M., Vlayen J., De Schutter H., Stordeur S., Decallonne B.: **Regional variation in thyroid cancer incidence in Belgium is associated with variation in thyroid imaging and thyroid disease management.** *J Clin Endocrinol Metab* 2013, 98(10):4063-71. <https://doi.org/10.1210/jc.2013-1705>
- 6) Werbrouck J., Bouche G., de Jonge E., Jacomen G., D'Hondt V., Denys H., Van Limbergen E., Vandermeersch B., De Schutter H., Van Eycken E., Goffin F., Amant F.: **Evaluation of the quality of the management of cancer of the corpus uteri-selection of relevant quality indicators and implementation in Belgium.** *Gynecol Oncol* 2013, 131(3):512-9. <https://doi.org/10.1016/j.ygyno.2013.10.001>



- 1) Kiderlen M., Bastiaannet E., Walsh P.M., Keating N.L., Schrodi S., Engel J., van de Water W., Ess S.M., Van Eycken L., Miranda A., de Munck L., van de Velde C.J., de Craen A.J., Liefers G.J.: **Surgical treatment of early stage breast cancer in elderly: an international comparison.** *Breast Cancer Res Treat.* 2012 Apr, 132(2):675-82. [10.1007/s10549-011-1892-5](https://doi.org/10.1007/s10549-011-1892-5)
- 2) Penninckx F., Beirens K., Fieuws S., Ceelen W., Demetter P., Haustermans K., Van de Stadt J., Vindevoghel K., on behalf of PROCARE: **Risk adjusted benchmarking of clinical anastomotic leakage rate after total mesorectal excision in the context of an improvement project.** *Colorectal Dis* 2012, 14(7):413-21. <https://doi.org/10.1111/j.1463-1318.2012.02977.x>
- 3) Stordeur S., Vrijens F., Devriese S., Beirens K., Van Eycken E., Vlayen J.: **Developing and measuring a set of process and outcome indicators for breast cancer.** *The Breast* 2012, 21:253-260. <https://doi.org/10.1016/j.breast.2011.10.003>
- 4) Vlayen J., Vrijens F., Devriese S., Beirens K., Van Eycken E., Stordeur S.: **Quality indicators for testicular cancer: A population-based study.** *European Journal of Cancer* 2012, 48:1133-1140. <https://doi.org/10.1016/j.ejca.2011.10.023>
- 5) Vrijens F., Stordeur S., Beirens K., Devriese S., Van Eycken E., Vlayen J.: **Effect of hospital volume on processes of care and 5-year survival after breast cancer: a population-based study of 25000 women.** *Breast* 2012, 21(3):261-6. doi: 10.1016/j.breast.2011.12.002. <https://10.1016/j.breast.2011.12.002>



- 1) Renard F., Van Eycken L., Arbyn M.: **High burden of breast cancer in Belgium: recent trends in incidence (1999-2006) and historical trends in mortality (1954-2006)**. *Arch Public Health* 2011, 69(1):2. [10.1186/0778-7367-69-2](https://doi.org/10.1186/0778-7367-69-2)
- 2) Zigon G., Berrino F., Gatta G., Sánchez M.J., van Dijk B., Van Eycken E., Francisci S.; EUROCARE Working Group: **Prognoses for head and neck cancers in Europe diagnosed in 1995-1999: a population-based study**. *Ann Oncol.* 2011 Jan, 22(1):165-74. <https://doi.org/10.1093/annonc/mdq306>

2010

- 1) Leonard D., Penninckx F., Fieuws S., Jouret-Mourin A., Sempoux C., Jehaes C., Van Eycken E.; PROCARE, a multidisciplinary Belgian Project on Cancer of the Rectum: **Factors predicting the quality of total mesorectal excision for rectal cancer**. *Ann Surg.* 2010 252(6):982-8. <https://doi.org/10.1097/SLA.0b013e3181efc142>
- 2) Renard F., Vankrunkelsven P., Van Eycken L., Henau K., Boniol M., Autier P.: **Decline in breast cancer incidence in the Flemish region of Belgium after a decline in hormonal replacement therapy**. *Ann Oncol* 2010 21(12):2356-60. <https://doi.org/10.1093/annonc/mdq240>
- 3) Van Calsteren K., Heyns L., De Smet F., Van Eycken L., Gziri M.M., Van Gemert W., Halaska M., Vergote I., Ottevanger N., Amant F. **Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes**. *J Clin Oncol.* 2010 28(4):683-9. <https://doi.org/10.1200/JCO.2009.23.2801>

2007

- 1) Nawrot T.S., Van Kersschaever G., Van Eycken E., Nemery B.: **Belgium: historical champion in asbestos consumption**. *Lancet* 2007 369(9574):1692 [https://doi.org/10.1016/S0140-6736\(07\)60776-4](https://doi.org/10.1016/S0140-6736(07)60776-4)

2005

- 1) Drijkoningen M., Bogers J.P., Bourgain C., Cuvelier C., Delvenne P., Gompel C., Saerens L., Thienpont L., Van Damme B., Van Eycken L., Verhest A., Weynand B.: **Cytopathology in Belgium**. *Cytopathology* 2005 16(2):100-104. <https://doi.org/10.1111/j.1365-2303.2004.00228.x>